| Objective:To investigate the clinical effects and adverse reactions of two neoadjuvant chemotherapy regimens in breast cancer patients before operation.Methods:A retrospective analysis was made of 80 patients which were diagnosed with breast cancer and received neoadjuvant chemotherapy from January 2013 to January2017.Eighty patients were randomly divided into two groups according to the different neoadjuvant chemotherapy regimens in a ratio of 1:1,which were control group and observation group.Among them,40 breast cancer patients were treated with epiadriamycin combined with cyclophosphamide neoadjuvant chemotherapy as the control group,and the other 40 patients were treated with docetaxel combined with epiadriamycin and cyclophosphamide neoadjuvant chemotherapy as the observation group.Every three weeks is a chemotherapy cycle,a total of four cycles of chemotherapy.After the end of neoadjuvant chemotherapy,the efficacy and adverse reactions of two groups of breast cancer patients after treatment were tested.Results:The overall effective rate of neoadjuvant chemotherapy for breast cancer patients in the observation group was 77.50%,while that for breast cancer patients in the control group was 55.00%.The difference between the two groups was statistically significant(P<0.05).During the period of neoadjuvant chemotherapy,the patients in both groups presented adverse reactions of decreased leukocyte count,nausea andvomiting,and liver and kidney function injury,and the differences were not statistically significant(P>0.05).Conclusion:The TEC regimen for preoperative chemotherapy with taxane and anthracycline chemotherapy is superior to the anthracycline EC regimen,which can significantly increase the therapeutic effect of breast cancer patients in neoadjuvant chemotherapy,accelerate the tumor shrinkage,and will not increase the clinical adverse reactions,providing a certain treatment basis for the choice of clinical neoadjuvant chemotherapy for breast cancer. |
PDF Full Text Request